Corporate Announcement
Security Code : 524804    Company : AUROPHARMA    
 
Announcement under Regulation 30 (LODR)-Joint VentureDownload PDFDownload XBRL
  Exchange Received Time  30/08/2019 17:42:55         Exchange Disseminated Time   30/08/2019 17:42:59              Time Taken   00:00:04
We inform you that our wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has on August 29, 2019 entered into an agreement with Shanghai LongJin Investment Company Ltd., China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co Ltd'., for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.
 

Disclaimer

Back To Announcements